Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2012 1
2013 2
2015 1
2018 1
2019 6
2020 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC.
Rogado J, Pozo F, Troule K, Sánchez-Torres JM, Romero-Laorden N, Mondejar R, Donnay O, Ballesteros A, Pacheco-Barcia V, Aspa J, Al-Shahrour F, Alfranca A, Colomer R. Rogado J, et al. Among authors: donnay o. Cancers (Basel). 2022 Jun 12;14(12):2898. doi: 10.3390/cancers14122898. Cancers (Basel). 2022. PMID: 35740564 Free PMC article.
SEOM clinical guidelines on nutrition in cancer patients (2018).
de Las Peñas R, Majem M, Perez-Altozano J, Virizuela JA, Cancer E, Diz P, Donnay O, Hurtado A, Jimenez-Fonseca P, Ocon MJ. de Las Peñas R, et al. Among authors: donnay o. Clin Transl Oncol. 2019 Jan;21(1):87-93. doi: 10.1007/s12094-018-02009-3. Epub 2019 Jan 8. Clin Transl Oncol. 2019. PMID: 30617923 Free PMC article.
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R. Rogado J, et al. Among authors: donnay o. Eur J Cancer. 2019 Mar;109:21-27. doi: 10.1016/j.ejca.2018.10.014. Epub 2019 Jan 22. Eur J Cancer. 2019. PMID: 30682533
Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies.
Rogado J, Romero-Laorden N, Sanchez-Torres JM, Ramos-Levi AM, Pacheco-Barcia V, Ballesteros AI, Arranz R, Lorenzo A, Gullon P, Garrido A, Serra López-Matencio JM, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondejar R, Colomer R. Rogado J, et al. Among authors: donnay o. Oncoimmunology. 2020 Apr 16;9(1):1751548. doi: 10.1080/2162402X.2020.1751548. eCollection 2020. Oncoimmunology. 2020. PMID: 32363123 Free PMC article.
14 results